284 related articles for article (PubMed ID: 11148373)
1. [The modulators of the estrogenic activity].
Kirkiacharian S
Ann Pharm Fr; 2000 Dec; 58(6):383-91. PubMed ID: 11148373
[TBL] [Abstract][Full Text] [Related]
2. [Antiestrogens--benefits of estrogens without their disadvantages?].
Välimäki MJ; Tiitinen A
Duodecim; 1998; 114(19):1885, 1887-8. PubMed ID: 11717742
[No Abstract] [Full Text] [Related]
3. Quinoids formed from estrogens and antiestrogens.
Bolton JL; Yu L; Thatcher GR
Methods Enzymol; 2004; 378():110-23. PubMed ID: 15038960
[No Abstract] [Full Text] [Related]
4. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Jordan VC
J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
[No Abstract] [Full Text] [Related]
5. [The pharmacology of estrogens].
Mohr K
Pharm Unserer Zeit; 2004; 33(5):360-4. PubMed ID: 15497330
[No Abstract] [Full Text] [Related]
6. [Antiestrogens: mechanism of action and clinical applications].
Barrón-González A; Arias-Martínez J; Castro-Romero I
Salud Publica Mex; 2001; 43(6):577-84. PubMed ID: 11816234
[TBL] [Abstract][Full Text] [Related]
7. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
9. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
11. [Modern approaches to hormone therapy of breast cancer as a reflection of pathogenesis of the disease].
Semiglazov VP
Vopr Onkol; 2001; 47(2):195-9. PubMed ID: 11383456
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
13. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
14. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
15. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
16. The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer.
McDonnell DP
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):871s-7s. PubMed ID: 15701880
[TBL] [Abstract][Full Text] [Related]
17. Current status of endocrine therapy for advanced breast cancer.
Bland KI
Ann Surg Oncol; 1999 Dec; 6(8 Suppl):4S-7S. PubMed ID: 10619452
[No Abstract] [Full Text] [Related]
18. Anti-oestrogenic prevention of breast cancer--the make or break point.
Powles TJ
Nat Rev Cancer; 2002 Oct; 2(10):787-94. PubMed ID: 12360281
[TBL] [Abstract][Full Text] [Related]
19. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
20. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
